Codix Group, a subsidiary of Colexa Biosensor Ltd, has achieved a significant milestone by receiving approval from the World Health Organization (WHO) to package WHO Prequalified Rapid Diagnostic Test kits at its factory in Nigeria.
This approval enables Colexa Biosensor to locally package the WHO Prequalified HIV Rapid Diagnostic Test in the country, positioning Nigeria as a key player in advancing healthcare production capabilities and improving access to life-saving diagnostics.
According to Codix Group, “The Standard Q HIV 1/2 Ab 3-Line Test is now the first WHO Prequalified HIV RDT approved for packaging within Africa, marking a historic feat for the continent.”
This accomplishment reflects the company’s dedication to strengthening Nigeria’s healthcare infrastructure and aligning with the President’s vision to enhance local manufacturing and innovation. Since its commissioning in December 2023, Colexa Biosensor has earned recognition from global health organizations, including WHO, Global Fund, UNITAID, FIND, and PEPFAR.
The factory’s operational capacity represents a significant step toward reducing dependence on imports, improving access to high-quality In-Vitro Diagnostics (IVDs), and fostering Nigeria’s healthcare value chain.
This approval also paves the way for procurement opportunities by Nigeria and international donors, further boosting local and global efforts to combat HIV. Codix Group expressed its pride in achieving this milestone and reaffirmed its commitment to elevating healthcare standards across the nation and beyond.
The achievement is expected to inspire further investment in local healthcare production, signaling a brighter future for the industry in Africa.
